OCARINA I, Phase Ib Study: Dose Selection of Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis

Authors
Category Primary study
JournalNeurology
Year 2024
This article has no abstract
Epistemonikos ID: c921a9ca88847908020b94d4a2691957f1ba2e9e
First added on: Feb 19, 2025